Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
CAMBRIDGE, Mass., Feb. 02, 2016 -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today announced that Thomas Mathers, Chief Executive Officer, will present a corporate overview at the BIO CEO & Investor Conference, being held in New York City February 8-9.
| BIO CEO & Investor Conference -- CoLucid Presentation Details | |||
| Date: | Tuesday, February 9 | ||
| Time: | 2:30pm Eastern Time | ||
| Location: | Waldorf Astoria, Conrad Room | ||
| Webcast: | http://www.veracast.com/webcasts/bio/ceoinvestor2016/45227430457.cfm | ||
About CoLucid Pharmaceuticals, Inc.
CoLucid was founded in 2005 and is developing oral lasmiditan for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.
Thomas Mathers Chief Executive Officer CoLucid Pharmaceuticals, Inc. (857) 285-6494 Hans Vitzthum Managing Director LifeSci Advisors, LLC. (212) 915-2568
